AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD
- Details
- Category: AstraZeneca
AstraZeneca today announced positive top-line results from the Phase III PINNACLE programme, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of PT003 to improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD).
GSK becomes partner in new global fund to accelerate dementia research
- Details
- Category: GlaxoSmithKline
GSK today announced it will be a key partner, with an investment of $25m (approx £17m), in a pioneering new global fund for dementia research. The Dementia Discovery Fund, which is being established by the UK government with initial commitments totalling $100m, brings together leading pharmaceutical companies, the UK government and Alzheimer's Research UK to address the rising threat posed by dementia by supporting research into future treatments.
PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack
- Details
- Category: AstraZeneca
AstraZeneca has announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial that investigated BRILINTA® (ticagrelor) tablets plus low dose aspirin, compared to placebo plus low dose aspirin, for the chronic secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study enrolment.
Bayer aspires to significantly expand Life Science businesses
- Details
- Category: Bayer
The Bayer Group aims to achieve strong sales and earnings growth for its Life Science businesses in the coming years. "We are also optimistic for the medium term and have great plans for the Life Science businesses," said CEO Dr. Marijn Dekkers on Wednesday at the "Meet Management" investor conference in Berlin.
GSK announces major new commitment to Asia
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) is strengthening its presence in Singapore by establishing a new global headquarters for Asia; further expanding its commitment to patients and consumers in the region, the company announced today.
FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
- Details
- Category: Novartis
Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved Zarxio(TM) (filgrastim-sndz) for all indications included in the reference product's label. Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under the Biologics Price Competition and Innovation Act.
FDA approves Opdivo (nivolumab) for the treatment of patients with previously treated metastatic squamous non-small cell lung cancer
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
More Pharma News ...
- AstraZeneca completes acquisition of rights to Actavis’ branded respiratory portfolio in the US and Canada
- Novartis announces completion of transactions with GSK
- Shire acquires Meritage Pharma
- Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
- Sanofi and Lead Pharma to develop treatments for autoimmune diseases
- GSK strengthens early stage vaccine pipeline with acquisition of GlycoVaxyn AG
- Roche acquires Signature Diagnostics to advance translational research for next generation sequencing (NGS) diagnostics